Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC Vaccine in Advanced Ovarian Cancer
NCT00703105Phase 2Unknown
- Sponsor
- Loyola University Chicago
- Start
- Oct 2008
- Primary completion
- Jul 2021
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous dendritic cell vaccine in ovarian cancer, sponsored by Loyola University Chicago. Primary endpoint: Immune Response to Vaccine at Day 62. Status: unknown.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00703105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00703105.